Your session is about to expire
← Back to Search
Other
PLN-74809 for Idiopathic Pulmonary Fibrosis (PLN-74809 Trial)
Phase 2
Waitlist Available
Led By Sydney Montesi, MD
Research Sponsored by Pliant Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from screening period (up to 28 days) to treatment period of 12 weeks, to 2 weeks after last dose
Awards & highlights
PLN-74809 Trial Summary
This trial at Mass. General is testing a treatment (PLN-74809) to see if it can help improve lung health.
Who is the study for?
This trial is for adults aged 40 or older with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within the last 8 years. They must have stable lung function and be on consistent treatment if taking IPF medications like nintedanib or pirfenidone. Smokers or those with recent infections, acute exacerbations, or using unapproved IPF treatments are excluded.Check my eligibility
What is being tested?
The study tests PLN-74809's effect on lung collagen deposition in IPF patients compared to a placebo over 12 weeks. It's double-blind, meaning neither participants nor researchers know who gets the real drug versus placebo, ensuring unbiased results.See study design
What are the potential side effects?
While specific side effects for PLN-74809 aren't listed here, common ones for new fibrosis drugs can include gastrointestinal issues, skin reactions, fatigue, headache and potential liver enzyme abnormalities.
PLN-74809 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from screening period (up to 28 days) to treatment period of 12 weeks, to 2 weeks after last dose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from screening period (up to 28 days) to treatment period of 12 weeks, to 2 weeks after last dose
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Secondary outcome measures
Secondary Safety and Tolerability
Other outcome measures
Exploratory 1
Exploratory 2
PLN-74809 Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: PLN-74809Experimental Treatment1 Intervention
160 mg PLN-74809
Group II: PlaceboPlacebo Group1 Intervention
Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PLN-74809
2020
Completed Phase 2
~260
Find a Location
Who is running the clinical trial?
Pliant Therapeutics, Inc.Lead Sponsor
7 Previous Clinical Trials
630 Total Patients Enrolled
4 Trials studying Idiopathic Pulmonary Fibrosis
426 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Sydney Montesi, MDPrincipal InvestigatorMass. General Hospital
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You were diagnosed with IPF within the past 8 years before the screening.Your lung function is at least 45% of what is expected for someone your age and size. If needed, your previous lung function test can be used if it was done within the month before screening.You are currently taking or planning to start a treatment for fibrosis that is not approved by the FDA for that specific condition.Your lung function is not good, and you have trouble breathing out air quickly.You have a current infection that could affect your lung function or the progression of the disease being studied.You have had a worsening of a lung condition called IPF in the past 6 months.You have smoked any kind of tobacco within the last 3 months.You are 40 years old or older.You can still join if you are taking nintedanib or pirfenidone for IPF as long as your dose has been the same for at least 3 months.Your lung function test must show a certain level of diffusing capacity for carbon monoxide (DLco), and if you have had this test before, it must have been done within the last month.
Research Study Groups:
This trial has the following groups:- Group 1: PLN-74809
- Group 2: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Idiopathic Pulmonary Fibrosis Patient Testimony for trial: Trial Name: NCT05621252 — Phase 2
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the participant count for this experiment?
"Indeed, the information on clinicaltrials.gov reveals that this trial is actively enrolling patients. It was first declared on July 13th 2022 and has since been updated November 14th 2022. This study requires 12 candidates to be recruited from 1 medical site."
Answered by AI
Are any new participants being enrolled in this clinical experiment?
"As of current, this trial is actively seeking candidates. The initial listing was posted on July 13th 2022 and the information was last revised on November 14th 2022 via clinicaltrials.gov."
Answered by AI
What potential risks would individuals be exposed to in taking PLN-74809?
"PLN-74809 has evidence of safety based on its Phase 2 trial, thus earning it a score of 2. However, no efficacy data exists for this medication yet."
Answered by AI
Who else is applying?
What state do they live in?
New York
What site did they apply to?
Massachusetts General Hospital
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0
Why did patients apply to this trial?
my mom is taking nitedanib for more than 3 months and it does not seem to heal. I need to help my mom a cure for my mom. please send me more detail on ahnpaul12@hotmail.com or 6466378096.
PatientReceived 2+ prior treatments
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger